Works matching DE "EFALIZUMAB"

Results: 98

T-cell clone associated with efalizumab therapy.

Published in:

Clinical & Experimental Dermatology, 2011, v. 36, n. 1, p. 99, doi. 10.1111/j.1365-2230.2010.03881.x

By:

Lynch, M.;
Murphy, K.;
Slaby, J.;
Kirby, B.

Publication type:

Article

Seborrhoeic keratoses appearing in sites of previous psoriasis plaques during treatment with efalizumab.

Published in:

Clinical & Experimental Dermatology, 2009, v. 34, n. 8, p. e564, doi. 10.1111/j.1365-2230.2009.03236.x

By:

Vestergaard, M. E.;
Kossard, S.;
Murrell, D. F.

Publication type:

Article

Efalizumab-induced thrombocytopenia: report of relapse after re-administration.

Published in:

Clinical & Experimental Dermatology, 2009, v. 34, n. 8, p. e914, doi. 10.1111/j.1365-2230.2009.03697.x

By:

Kiorpelidou, D.;
Tsiouri, G.;
Gaitanis, G.;
Akritidis, N.;
Bassukas, I. D.

Publication type:

Article

Migraine with aura induced by efalizumab.

Published in:

2009

By:

Kluger, N.;
Heroum, C.;
Michot, C.;
Guillot, B.;
Bessis, D.

Publication type:

Letter

Efalizumab treatment of psoriasis vulgaris: a cohort study in outpatient clinical practice.

Published in:

Clinical & Experimental Dermatology, 2009, v. 34, n. 4, p. 469, doi. 10.1111/j.1365-2230.2008.02993.x

By:

Puig, L.;
Roé, E.;
García-Navarro, X.;
Corella, F.;
Alomar, A.

Publication type:

Article

DRESS syndrome caused by efalizumab: comment.

Published in:

2009

By:

De Groot, M.;
De Rie, M. A.;
Bos, J. D.

Publication type:

Letter

Successful treatment of recalcitrant malar rash in a patient with cutaneous lupus erythematosus with efalizumab.

Published in:

2008

By:

Hamprecht, A.;
Tüting, T.;
Bieber, T.;
Wenzel, J.

Publication type:

Letter

Safety of Efalizumab Therapy in Patients with Moderate to Severe Psoriasis: An Open-Label Extension of a Phase IIIb Trial.

Published in:

Drug Safety, 2008, v. 31, n. 8, p. 715, doi. 10.2165/00002018-200831080-00008

By:

Hamilton, Tiffani;
Menter, Alan;
Caro, Ivor;
Compton, Peter;
Sobell, Jeffrey;
Papp, Kim A

Publication type:

Article

US FDA warns of serious risks with psoriasis drug Raptiva®.

Published in:: Expert Review of Anti-infective Therapy, 2009, v. 7, n. 4, p. 393
Publication type:: Article

Prediction of the pharmacokinetics, pharmacodynamics, and efficacy of a monoclonal antibody, using a physiologically based pharmacokinetic FcRn model.

Published in:

Frontiers in Immunology, 2015, v. 5, p. 1, doi. 10.3389/fimmu.2014.00670

By:

Chetty, Manoranjenni;
Linzhong Li;
Rose, Rachel;
Machavaram, Krishna;
Jamei, Masoud;
Rostami-Hodjegan, Amin;
Gardner, Iain;
Frenkel, Dan;
Olive, Daniel

Publication type:

Article

11. Psoriasis, Acne, etc.

Published in:: 2005
Publication type:: Abstract

Efalizumab, a reversible T-cell modulator for psoriasis.

Published in:

Journal of Cutaneous Medicine & Surgery, 2005, v. 9, p. 4, doi. 10.1007/s10227-006-0101-3

By:

Shear, Neil H.;
Langley, Richard G.;
Ho, Vincent

Publication type:

Article

Strategies for optimizing treatment with efalizumab in moderate to severe psoriasis.

Published in:

Journal of Cutaneous Medicine & Surgery, 2005, v. 9, p. 26, doi. 10.1007/s10227-006-0104-0

By:

Papp, Kim A.;
Ho, Vincent;
Langley, Richard;
Lynde, Charles;
Poulin, Yves;
Shear, Neil;
Toole, John;
Zip, Catherine

Publication type:

Article

Efalizumab: Integrating a new biologic agent into the long-term management of moderate to severe plaque psoriasis.

Published in:

Journal of Cutaneous Medicine & Surgery, 2005, v. 9, p. 1, doi. 10.1007/s10227-006-0100-4

By:

Lynde, Charles

Publication type:

Article

A favourable benefit/risk ratio with efalizumab: A review of the clinical evidence.

Published in:

Journal of Cutaneous Medicine & Surgery, 2005, v. 9, p. 10, doi. 10.1007/s10227-006-0102-2

By:

Poulin, Yves;
Papp, Kim A.;
Carey, Wayne;
Gulliver, Wayne;
Gupta, Aditya K.

Publication type:

Article

Safety labeling updates & new warnings.

Published in:: Formulary, 2008, v. 43, n. 11, p. 425
Publication type:: Article

Biologic psoriasis treatment options expanding.

Published in:: Formulary, 2007, v. 42, n. 5, p. 316
Publication type:: Article

Cutaneous malignancies during treatment with efalizumab and infliximab: When temporal relationship does not mean causality.

Published in:

Journal of Dermatological Treatment, 2011, v. 22, n. 4, p. 229, doi. 10.3109/09546631003681086

By:

Lernia, Vito Di;
Ricci, Cinzia

Publication type:

Article

Economic evaluation of biologic therapies for the treatment of moderate to severe psoriasis in the United States.

Published in:

Journal of Dermatological Treatment, 2011, v. 22, n. 2, p. 65, doi. 10.3109/09546630903551258

By:

Anis, Aslam H.;
Bansback, Nick;
Sizto, Sonia;
Gupta, Shiraz R.;
Willian, Mary K.;
Feldman, Steve R.

Publication type:

Article

Efalizumab discontinuation: A practical strategy.

Published in:

Journal of Dermatological Treatment, 2009, v. 20, n. 3, p. 132, doi. 10.1080/09546630902984596

By:

Pugashetti, Rupa;
Koo, John

Publication type:

Article

Efalizumab-induced guttate psoriasis. Successful management and re-treatment.

Published in:

Journal of Dermatological Treatment, 2008, v. 19, n. 3, p. 182, doi. 10.1080/09546630701691236

By:

Balato, Anna;
La Bella, Serena;
Gaudiello, Francesca;
Balato, Nicola

Publication type:

Article

Use of etanercept for psoriatic arthritis in the dermatology clinic: The Experience Diagnosing, Understanding Care, and Treatment with Etanercept (EDUCATE) study.

Published in:

Journal of Dermatological Treatment, 2006, v. 17, n. 6, p. 343, doi. 10.1080/09546630600967166

By:

Gottlieb, Alice B.;
Kircik, Leon;
Eisen, Drore;
Mark Jackson, J.;
Boh, Erin E.;
Strober, Bruce E.;
Frankel, Ellen;
Amt Xia, H.;
Stevens, Seth R.

Publication type:

Article

New-onset, debilitating arthritis in psoriasis patients receiving efalizumab.

Published in:

Journal of Dermatological Treatment, 2006, v. 17, n. 6, p. 353, doi. 10.1080/09546630600967406

By:

Myers, Wendy A.;
Najarian, David;
Gottlieb, Alice B.

Publication type:

Article

HEALTH AGENCIES UPDATE.

Published in:

JAMA: Journal of the American Medical Association, 2009, v. 301, n. 20, p. 2085

By:

Kuehn, Bridget M.

Publication type:

Article

BIOLOGICAL THERAPY OF PSORIASIS.

Published in:

Indian Journal of Dermatology, 2010, v. 55, n. 2, p. 161, doi. 10.4103/0019-5154.62754

By:

Sivamani, Raja K.;
Correa, Genevieve;
Ono, Yoko;
Bowen, Michael P.;
Raychaudhuri, Siba P.;
Maverakis, Emanual

Publication type:

Article

Efalizumab, a human monoclonal anti-CD11a antibody, in the treatment of moderate to severe Crohn's Disease: an open-label pilot study.

Published in:

2011

By:

James, Dustin;
Seo, Da;
Chen, Jiajing;
Vemulapalli, Caroline;
Stone, Christian;
James, Dustin G;
Seo, Da Hea;
Stone, Christian D

Publication type:

journal article

Guillain-Barré syndrome after short-course efalizumab treatment.

Published in:

2010

By:

Turatti, Marco;
Tamburin, Stefano;
Idone, Domenico;
Praitano, Maria;
Zanette, Giampietro

Publication type:

Letter

Weight gain and tumour necrosis factor-alpha inhibitors in patients with psoriasis.

Published in:

Australasian Journal of Dermatology, 2013, v. 54, n. 4, p. 259, doi. 10.1111/ajd.12044

By:

Tan, Eugene;
Baker, Christopher;
Foley, Peter

Publication type:

Article

Immunotargeting in the management of psoriasis.

Published in:

ImmunoTargets & Therapy, 2013, v. 2, p. 51, doi. 10.2147/ITT.S32038

By:

Kaffenberger, Benjamin H.;
Kaffenberger, Thomas M.;
Wong, Henry K.

Publication type:

Article

Adalimumab in the treatment of moderate-to-severe chronic plaque psoriasis in patients switching from other biologics.

Published in:

Journal of the European Academy of Dermatology & Venereology, 2015, v. 29, n. 9, p. 1742, doi. 10.1111/jdv.12981

By:

Sator, P.;
Richter, L.;
Saxinger, W.;
Vasiljevic, M.;
Stingl, G.

Publication type:

Article

Sequential treatment with biologics: switching from efalizumab to etanercept in 35 patients with high-need psoriasis Antoniou et al. Switching between biological agents for the treatment of psoriasis.

Published in:

Journal of the European Academy of Dermatology & Venereology, 2010, v. 24, n. 12, p. 1413, doi. 10.1111/j.1468-3083.2010.03661.x

By:

Antoniou, C.;
Dessinioti, C.;
Vergou, T.;
Stratigos, A. J.;
Avgerinou, G.;
Kostaki, M.;
Katsambas, A.

Publication type:

Article

Efalizumab for severe refractory atopic eczema: retrospective study on 11 cases.

Published in:

Journal of the European Academy of Dermatology & Venereology, 2010, v. 24, n. 7, p. 837, doi. 10.1111/j.1468-3083.2009.03202.x

By:

Ibler, K.;
Dam, T. N.;
Gniadecki, R.;
Kragballe, K.;
Jemec, G. B. E.;
Agner, T.

Publication type:

Article

Retrospective analysis of systemic treatments for psoriasis patients attending a Psocare center in Florence. Relevance of biological drugs use and comorbidities.

Published in:

Journal of the European Academy of Dermatology & Venereology, 2010, v. 24, n. 5, p. 555, doi. 10.1111/j.1468-3083.2009.03464.x

By:

Prignano, F.;
Pescitelli, L.;
Ricceri, F.;
Lotti, T.

Publication type:

Article

Acrodermatitis continua of Hallopeau responding to efalizumab therapy.

Published in:

2009

By:

Balato, N.;
Gallo, L.;
Balato, A.;
La Bella, S.;
Ayala, F.

Publication type:

Letter

Refractory discoid lupus erythematosus: response to efalizumab.

Published in:

2009

By:

Rodríguez -Lojo, R.;
Paradela, S.;
Martínez-Gómez, W.;
Fernández-Torres, R.;
Fonseca, E.

Publication type:

Letter

Efalizumab for severe palmo-plantar psoriasis: an open-label pilot trial in five patients.

Published in:

Journal of the European Academy of Dermatology & Venereology, 2009, v. 23, n. 4, p. 415, doi. 10.1111/j.1468-3083.2008.03062.x

By:

Brunasso, A. M. G.;
Salvini, C.;
Massone, C.

Publication type:

Article

Successful treatment of alopecia areata with efalizumab.

Published in:

2008

By:

Kolde, G.;
Meffert, H.;
Rowe, E.

Publication type:

Letter

Plantar exfoliation and desquamation during efalizumab therapy.

Published in:

2008

By:

Adíşen, E;
Gürer, MA

Publication type:

Letter

Clinical effectiveness and safety experience with efalizumab in the treatment of patients with moderate-to-severe plaque psoriasis in Taiwan: results of an open-label, single-arm pilot study.

Published in:

Journal of the European Academy of Dermatology & Venereology, 2008, v. 22, n. 3, p. 345, doi. 10.1111/j.1468-3083.2007.02430.x

By:

Tsai, T. F.;
Liu, M. T.;
Liao, Y. H.;
Licu, D.

Publication type:

Article

Combination of efalizumab and acitretin in chronic plaque psoriasis.

Published in:

2008

By:

Gisondi, P.;
Girolomoni, G.

Publication type:

Letter

Eruptive papules during efalizumab (anti-CD11a) therapy of psoriasis vulgaris: a case series.

Published in:

BMC Dermatology, 2007, v. 7, p. 2, doi. 10.1186/1471-5945-7-2

By:

Lowes, Michelle A;
Chamian, Francesca;
Abello, Maria V;
Craig6Leonardi;
Dummer, Wolfgang;
Papp, Kim;
Krueger, James G

Publication type:

Article

Approaches to discontinuing efalizumab: an open-label study of therapies for managing inflammatory recurrence.

Published in:

BMC Dermatology, 2006, v. 6, p. 9, doi. 10.1186/1471-5945-6-9

By:

Papp, Kim A.;
Toth, Darryl;
Rosoph, Les

Publication type:

Article

Evaluation of efalizumab using safe psoriasis control.

Published in:

BMC Dermatology, 2006, v. 6, p. 8, doi. 10.1186/1471-5945-6-8

By:

Papp, Kim A.;
Henninger, Eric

Publication type:

Article

Efalizumab Tedavisinin Kesilmesinin Psoriasisli Hastalarda Ortaya Çıkardığı Sorunlar.

Published in:

Archives of the Turkish Dermatology & Venerology / Turkderm, 2010, v. 44, n. 1, p. 19

By:

Adışen, Esra;
Tezel, Fulya;
Gürer, Mehmet Ali

Publication type:

Article

Efalizumab effective and safe in moderate to severe psoriasis.

Published in:: British Journal of Hospital Medicine (17508460), 2008, v. 69, n. 10, p. 553
Publication type:: Article

Balancing Immunity and Immunosuppression: Vaccinating Patients Receiving Treatment with Efalizumab.

Published in:

Journal of Investigative Dermatology, 2008, v. 128, n. 11, p. 2567, doi. 10.1038/jid.2008.291

By:

Marmon, Shana;
Strober, Bruce E.

Publication type:

Article

Effect of Therapeutic Integrin (CD11a) Blockade with Efalizumab on Immune Responses to Model Antigens in Humans: Results of a Randomized, Single Blind Study.

Published in:

Journal of Investigative Dermatology, 2008, v. 128, n. 11, p. 2615, doi. 10.1038/jid.2008.98

By:

Krueger, James G.;
Ochs, Hans D.;
Patel, Piyush;
Gilkerson, Ellen;
Guttman-Yassky, Emma;
Dummer, Wolfgang

Publication type:

Article

Efalizumab Therapy for Atopic Dermatitis Causes Marked Increases in Circulating Effector Memory CD4+ T Cells That Express Cutaneous Lymphocyte Antigen.

Published in:

Journal of Investigative Dermatology, 2008, v. 128, n. 5, p. 1173, doi. 10.1038/sj.jid.5701169

By:

Harper, Erin G.;
Simpson, Eric L.;
Takiguchi, Rodd H.;
Boyd, Miranda D.;
Kurtz, Stephen E.;
Bakke, Antony C.;
Blauvelt, Andrew

Publication type:

Article

A mathematical analysis of rebound in a target-mediated drug disposition model: II. With feedback.

Published in:

Journal of Mathematical Biology, 2017, v. 75, n. 1, p. 33, doi. 10.1007/s00285-016-1073-6

By:

Aston, Philip;
Derks, Gianne;
Agoram, Balaji;
Graaf, Piet

Publication type:

Article

Glutathione peroxidase activity in the blood cells of psoriatic patients correlates with their responsiveness to Efalizumab.

Published in:

Free Radical Research, 2011, v. 45, n. 5, p. 585, doi. 10.3109/10715762.2011.560150

By:

Pastore, Saveria;
Mariani, Valentina;
Lulli, Daniela;
Gubinelli, Emanuela;
Raskovic, Desanka;
Mariani, Serena;
Stancato, Andrea;
de Luca, Chiara;
Pecorelli, Alessandra;
Valacchi, Giuseppe;
Potapovich, Alla I.;
Kostyuk, Vladimir A.;
Korkina, Liudmila G.

Publication type:

Article